改善病情抗风湿药治疗病毒感染的机制及临床研究进展  

Mechanism and clinical research progress of disease-modifying anti-rheumatic drugs in the treatment of viral infection

作　　者：焦桐 陈昊 杨静[1] 刘芮妮 张舒恬 吴沅皞[1] Jiao Tong;Chen Hao;Yang Jing;Liu Ruini;Zhang Shutian;Wu Yuanhao(Department of Rheumatology and Immunology,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Key Laboratory of Translational Research of Traditional Chinese Medicine Prescription and Syndrome,Tianjin 300380,China)

机构地区：[1]天津中医药大学第一附属医院风湿免疫科,国家中医针灸临床医学研究中心,天津市中医方证转化研究重点实验室,天津300380

出　　处：《中国医药》2022年第3期456-461,共6页China Medicine

基　　金：天津市卫生计生行业高层次人才选拔培养工程项目(02005);天津中医药大学第一附属医院新型冠状病毒肺炎专项科研课题(2020003)。

摘　　要：改善病情抗风湿药(DMARDs)包括传统合成DMARDs、生物DMARDs和靶向合成DMARDs,近年来多项研究发现这一类药物也同样具有广泛的抗病毒作用,甚至具有治疗新型冠状病毒感染的可能。DMARDs通过多种复杂机制对病毒产生抑制作用,涉及了多个靶点和通路,如白细胞介素6信号通路、氧化还原通路、JAK通路等,在治疗病毒感染方面具有非常广阔的前景,现有的研究拓展了DMARDs药物的应用范围,使其有望成为一类独特的抗病毒药物。Disease-modifying anti-rheumatic drugs(DMARDs)include conventional synthesis DMARDs,biosynthesis DMARDs,and targeted synthesis DMARDs.In recent years,many studies have found that DMARDs have extensive antiviral effects,and even have the possibility for treating 2019 novel corona virus infection.DMARDs inhibit the virus through a variety of complex mechanisms,involving multiple targets and pathways,such as interleukin-6 signal pathway,redox pathway,JAK pathway and so on.DMARDs have a very broad prospect in the treatment of viral infection.Current research results expand the applicated scope of DMARDs,which are expected to become a kind of unique antiviral drugs.

关 键 词：改善病情抗风湿药 病毒 临床研究 新型冠状病毒肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]